Opendata, web and dolomites

TKI resistance SIGNED

Resistance mechanisms to tyrosine kinase inhibitors in solid tumors

Total Cost €


EC-Contrib. €






 TKI resistance project word cloud

Explore the words cloud of the TKI resistance project. It provides you a very rough idea of what is the project "TKI resistance" about.

patients    tolerate    sensitizers    validate    adaptive    emergence    tolerant    translational    populations    designs    reprogrammation    cellular    modifiers    over    tyrosine    inhibitor    persistor    treatments    laboratory    cancer    few    subsequent    successfully    therapies    extremely    involve    vitro    strategy    rational    expanded    alternative    innovative    probably    guidance    screen    acquired    develops    cells    cell    persistors    requisite    lines    acquisition    inhibitors    combinatorial    escape    oncogene    agents    resistant    elucidate    tkis    patient    drug    apoptosis    mechanisms    resistance    groups    performed    screening    understand    standardized    models    kinase    tki    ultimately    stage    xenografts    interfere    absolute    additionally    biopsies    strategies    screens    epigenetic    single    establishing    molecular    therapeutic    systematic    driver    addicted    discovery    whereby    arsenal    addiction    chemotherapeutic    limited    overcome    worldwide    scrutinize   

Project "TKI resistance" data sheet

The following table provides information about the project.


Organization address
address: Rue Camille Desmoulins 39
postcode: 94805

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website
 Total cost 1˙500˙000 €
 EC max contribution 1˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2021-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) coordinator 1˙500˙000.00


 Project objective

Over the past 10 years, the chemotherapeutic arsenal has been expanded to include molecular-targeted therapies based on the principle that cancer cells become addicted to a single driver oncogene. However, use of these new therapies is limited due to development of acquired resistance. To fully understand how resistance develops, patient-derived models are an absolute pre-requisite, but establishing them remains extremely challenging. Few groups worldwide have successfully implemented a systematic standardized approach to facilitate translational cancer research discovery. My project aims to provide rational therapeutic guidance for combinatorial or adaptive designs to overcome acquired resistance to tyrosine kinase inhibitors (TKIs) in patients with oncogene-addiction. By establishing new laboratory models of resistance directly from patient biopsies (patient derived cell lines and xenografts) I will elucidate the molecular mechanisms whereby cancer cells escape targeted treatments. I will then implement innovative approaches to overcome resistance using TKI combinatorial screens, apoptosis sensitizers and by screening for epigenetic modifiers. Additionally, I will scrutinize the emergence of resistance acquisition in vitro. Current working models involve “persistor” cellular populations able to tolerate the TKI and, in a subsequent step, to become fully resistant to the drug. This drug tolerant persistor stage most probably involves epigenetic reprogrammation. An epigenetic inhibitor screen will be performed to identify agents able to interfere with the emergence of persistors and ultimately with the acquisition of TKI resistance. These results should provide an alternative strategy to validate innovative combinatorial drug strategies to avoid emergence of resistance in patients.


year authors and title journal last update
List of publications.
2019 Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z Rizvi, Rosa L Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hol
Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
published pages: clincanres.1104., ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-19-1104
Clinical Cancer Research 2019-10-10
2019 Francesco Facchinetti, Antoine Hollebecque, Rastilav Bahleda, Yohann Loriot, Ken A Olaussen, Christophe Massard, Luc Friboulet
Facts and new hopes on selective FGFR inhibitors in solid tumors
published pages: clincanres.2035., ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-19-2035
Clinical Cancer Research 2019-10-10
2018 Gonzalo Recondo, Francesco Facchinetti, Ken A. Olaussen, Benjamin Besse, Luc Friboulet
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
published pages: , ISSN: 1759-4774, DOI: 10.1038/s41571-018-0081-4
Nature Reviews Clinical Oncology 2019-09-09

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TKI RESISTANCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TKI RESISTANCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

DYNAPOL (2019)

Modeling approaches toward bioinspired dynamic materials

Read More  

MuFLOART (2018)

Microbiological fluorescence observatory for antibiotic resistance tracking

Read More  

FuncMAB (2019)

High-throughput single-cell phenotypic analysis of functional antibody repertoires

Read More